Please enable JavaScript to continue using this application.

Compare $ANIK vs $LCTX | Chartloom

Compare

$ANIK vs $LCTX

Anika Therapeutics Inc · Lineage Cell Therapeutics Inc

ANIK

Anika Therapeutics Inc

LCTX

Lineage Cell Therapeutics Inc

Compare $ANIK vs $LCTX

Comparing Anika Therapeutics Inc and Lineage Cell Therapeutics Inc

ANIKAnika Therapeutics Inc

LCTXLineage Cell Therapeutics Inc

ANIKAnika Therapeutics Inc

Market cap

$262M

P/E (TTM)

—

Forward P/E (NTM)

57.30x

Forward P/S (NTM)

2.09x

Rev growth (TTM)

-2.5%

YTD performance

109.4%

52W performance

111.9%

FCF yield

0.2%

LCTXLineage Cell Therapeutics Inc

Market cap

$248M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

28.49x

Rev growth (TTM)

-37.1%

YTD performance

-39.4%

52W performance

-42.5%

FCF yield

-10.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ANIK

LCTX

Detailed metrics comparison

ANIK

Anika Therapeutics Inc

LCTX

Lineage Cell Therapeutics Inc

Market Cap

ANIK$262M

LCTX$248M

Enterprise Value

ANIK$224M

LCTX$210M

Price

ANIK$19.58

LCTX$0.99

P/E Ratio

ANIKN/A

LCTXN/A

P/S Ratio

ANIK2.17x

LCTX18.94x

EV/Sales

ANIK1.85x

LCTX16.09x

EV/EBITDA

ANIK84.97x

LCTX0.00x

P/B Ratio

ANIK1.86x

LCTX3.86x

P/FCF Ratio

ANIK466.16x

LCTXN/A

EV/FCF

ANIK397.81x

LCTX-8.48x

PEG Ratio

ANIKN/A

LCTXN/A

Forward P/E (NTM)

ANIK57.30x

LCTXN/A

Forward P/S (NTM)

ANIK2.09x

LCTX28.49x

Revenue (TTM)

ANIK$121M

LCTX$13M

Revenue Growth (YoY)

ANIK-2.5%

LCTX-37.1%

Forward Rev Growth

ANIK5.2%

LCTX-16.6%

Gross Margin (TTM)

ANIK62.2%

LCTX94.1%

Operating Margin (TTM)

ANIK0.0%

LCTX0.0%

EBITDA Margin (TTM)

ANIK2.2%

LCTX-199.6%

Net Margin (TTM)

ANIK-3.1%

LCTX-246.6%

FCF Margin (TTM)

ANIK0.5%

LCTX-189.7%

Net Income (TTM)

ANIK$-4M

LCTX$-32M

FCF (TTM)

ANIK$562K

LCTX$-25M

EPS (TTM)

ANIK-$0.28

LCTX-$0.13

ROE (TTM)

ANIK-270.0%

LCTX-7114.0%

ROA (TTM)

ANIK-204.0%

LCTX-3087.0%

ROIC (TTM)

ANIK-270.0%

LCTX-7104.0%

Cash

ANIK$38M

LCTX$37M

Debt

ANIK$0

LCTX$48K

Net Cash/Debt

ANIK$38M

LCTX$37M

Current Ratio (TTM)

ANIK4.48x

LCTX6.61x

Quick Ratio (TTM)

ANIK3.05x

LCTX6.44x

Debt/Equity (TTM)

ANIK0.00x

LCTX0.00x

Debt/Assets (TTM)

ANIK0.0%

LCTX0.0%

Interest Coverage (TTM)

ANIKN/A

LCTXN/A

Net Debt/EBITDA (TTM)

ANIK0.00x

LCTX0.00x

Beta

ANIK0.23

LCTX1.67

52W Performance

ANIK111.9%

LCTX-42.5%

YTD Performance

ANIK109.4%

LCTX-39.4%

% from 52W High

ANIK-14.4%

LCTX-52.4%

% from 52W Low

ANIK125.8%

LCTX12.7%

Asset Turnover (TTM)

ANIK0.65x

LCTX0.07x

FCF Yield (TTM)

ANIK0.2%

LCTX-10.0%

Earnings Yield (TTM)

ANIK-1.4%

LCTX-13.0%

Dividend Yield (TTM)

ANIKN/A

LCTXN/A

Rule of 40

ANIK-2.0

LCTX-226.8

EV/GP/RG

ANIK0.81

LCTXN/A

Ticker research

View ANIK research View LCTX research

Metric	ANIK Anika Therapeutics Inc	LCTX Lineage Cell Therapeutics Inc
Market & Valuation
Market Cap	$262M	$248M
Enterprise Value	$224M	$210M
Price	$19.58	$0.99
P/E Ratio	N/A	N/A
P/S Ratio	2.17x	18.94x
EV/Sales	1.85x	16.09x
EV/EBITDA	84.97x	0.00x
P/B Ratio	1.86x	3.86x
P/FCF Ratio	466.16x	N/A
EV/FCF	397.81x	-8.48x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	57.30x	N/A
Forward P/S (NTM)	2.09x	28.49x
Revenue & Growth
Revenue (TTM)	$121M	$13M
Revenue Growth (YoY)	-2.5%	-37.1%
Forward Rev Growth	5.2%	-16.6%
Profitability
Gross Margin (TTM)	62.2%	94.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	2.2%	-199.6%
Net Margin (TTM)	-3.1%	-246.6%
FCF Margin (TTM)	0.5%	-189.7%
Net Income (TTM)	$-4M	$-32M
FCF (TTM)	$562K	$-25M
EPS (TTM)	-$0.28	-$0.13
ROE (TTM)	-270.0%	-7114.0%
ROA (TTM)	-204.0%	-3087.0%
ROIC (TTM)	-270.0%	-7104.0%
Financial Health
Cash	$38M	$37M
Debt	$0	$48K
Net Cash/Debt	$38M	$37M
Current Ratio (TTM)	4.48x	6.61x
Quick Ratio (TTM)	3.05x	6.44x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.23	1.67
52W Performance	111.9%	-42.5%
YTD Performance	109.4%	-39.4%
% from 52W High	-14.4%	-52.4%
% from 52W Low	125.8%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.65x	0.07x
FCF Yield (TTM)	0.2%	-10.0%
Earnings Yield (TTM)	-1.4%	-13.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2.0	-226.8
EV/GP/RG	0.81	N/A
Ticker research	View ANIK research	View LCTX research

Valuation

P/S Ratio

ANIK

2.17x

LCTX

18.94x

EV/FCF

LCTX

-8.48x

ANIK

397.81x

Growth & revenue

Revenue Growth TTM

ANIK

-2.5%

LCTX

-37.1%

Forward Revenue Growth

ANIK

5.2%

LCTX

-16.6%

Profitability & performance

Gross Margin

LCTX

94.1%

ANIK

62.2%

ROE

ANIK

-270.0%

LCTX

-7114.0%

FCF Yield %

ANIK

0.2%

LCTX

-10.0%

52-Week Performance

ANIK

111.9%

LCTX

-42.5%

Detailed metrics comparison

ANIK

Anika Therapeutics Inc

LCTX

Lineage Cell Therapeutics Inc

Market Cap

ANIK$262M

LCTX$248M

Enterprise Value

ANIK$224M

LCTX$210M

Price

ANIK$19.58

LCTX$0.99

P/E Ratio

ANIKN/A

LCTXN/A

P/S Ratio

ANIK2.17x

LCTX18.94x

EV/Sales

ANIK1.85x

LCTX16.09x

EV/EBITDA

ANIK84.97x

LCTX0.00x

P/B Ratio

ANIK1.86x

LCTX3.86x

P/FCF Ratio

ANIK466.16x

LCTXN/A

EV/FCF

ANIK397.81x

LCTX-8.48x

PEG Ratio

ANIKN/A

LCTXN/A

Forward P/E (NTM)

ANIK57.30x

LCTXN/A

Forward P/S (NTM)

ANIK2.09x

LCTX28.49x

Revenue (TTM)

ANIK$121M

LCTX$13M

Revenue Growth (YoY)

ANIK-2.5%

LCTX-37.1%

Forward Rev Growth

ANIK5.2%

LCTX-16.6%

Gross Margin (TTM)

ANIK62.2%

LCTX94.1%

Operating Margin (TTM)

ANIK0.0%

LCTX0.0%

EBITDA Margin (TTM)

ANIK2.2%

LCTX-199.6%

Net Margin (TTM)

ANIK-3.1%

LCTX-246.6%

FCF Margin (TTM)

ANIK0.5%

LCTX-189.7%

Net Income (TTM)

ANIK$-4M

LCTX$-32M

FCF (TTM)

ANIK$562K

LCTX$-25M

EPS (TTM)

ANIK-$0.28

LCTX-$0.13

ROE (TTM)

ANIK-270.0%

LCTX-7114.0%

ROA (TTM)

ANIK-204.0%

LCTX-3087.0%

ROIC (TTM)

ANIK-270.0%

LCTX-7104.0%

Cash

ANIK$38M

LCTX$37M

Debt

ANIK$0

LCTX$48K

Net Cash/Debt

ANIK$38M

LCTX$37M

Current Ratio (TTM)

ANIK4.48x

LCTX6.61x

Quick Ratio (TTM)

ANIK3.05x

LCTX6.44x

Debt/Equity (TTM)

ANIK0.00x

LCTX0.00x

Debt/Assets (TTM)

ANIK0.0%

LCTX0.0%

Interest Coverage (TTM)

ANIKN/A

LCTXN/A

Net Debt/EBITDA (TTM)

ANIK0.00x

LCTX0.00x

Beta

ANIK0.23

LCTX1.67

52W Performance

ANIK111.9%

LCTX-42.5%

YTD Performance

ANIK109.4%

LCTX-39.4%

% from 52W High

ANIK-14.4%

LCTX-52.4%

% from 52W Low

ANIK125.8%

LCTX12.7%

Asset Turnover (TTM)

ANIK0.65x

LCTX0.07x

FCF Yield (TTM)

ANIK0.2%

LCTX-10.0%

Earnings Yield (TTM)

ANIK-1.4%

LCTX-13.0%

Dividend Yield (TTM)

ANIKN/A

LCTXN/A

Rule of 40

ANIK-2.0

LCTX-226.8

EV/GP/RG

ANIK0.81

LCTXN/A

Ticker research

View ANIK research View LCTX research

Metric	ANIK Anika Therapeutics Inc	LCTX Lineage Cell Therapeutics Inc
Market & Valuation
Market Cap	$262M	$248M
Enterprise Value	$224M	$210M
Price	$19.58	$0.99
P/E Ratio	N/A	N/A
P/S Ratio	2.17x	18.94x
EV/Sales	1.85x	16.09x
EV/EBITDA	84.97x	0.00x
P/B Ratio	1.86x	3.86x
P/FCF Ratio	466.16x	N/A
EV/FCF	397.81x	-8.48x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	57.30x	N/A
Forward P/S (NTM)	2.09x	28.49x
Revenue & Growth
Revenue (TTM)	$121M	$13M
Revenue Growth (YoY)	-2.5%	-37.1%
Forward Rev Growth	5.2%	-16.6%
Profitability
Gross Margin (TTM)	62.2%	94.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	2.2%	-199.6%
Net Margin (TTM)	-3.1%	-246.6%
FCF Margin (TTM)	0.5%	-189.7%
Net Income (TTM)	$-4M	$-32M
FCF (TTM)	$562K	$-25M
EPS (TTM)	-$0.28	-$0.13
ROE (TTM)	-270.0%	-7114.0%
ROA (TTM)	-204.0%	-3087.0%
ROIC (TTM)	-270.0%	-7104.0%
Financial Health
Cash	$38M	$37M
Debt	$0	$48K
Net Cash/Debt	$38M	$37M
Current Ratio (TTM)	4.48x	6.61x
Quick Ratio (TTM)	3.05x	6.44x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.23	1.67
52W Performance	111.9%	-42.5%
YTD Performance	109.4%	-39.4%
% from 52W High	-14.4%	-52.4%
% from 52W Low	125.8%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.65x	0.07x
FCF Yield (TTM)	0.2%	-10.0%
Earnings Yield (TTM)	-1.4%	-13.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2.0	-226.8
EV/GP/RG	0.81	N/A
Ticker research	View ANIK research	View LCTX research